Tags

Type your tag names separated by a space and hit enter

I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life.
World J Gastroenterol 2014; 20(26):8709-16WJ

Abstract

AIM

To determine the dose-related effects of a novel probiotic combination, I.31, on irritable bowel syndrome (IBS)-related quality of life (IBS-QoL).

METHODS

A multicenter, randomized, double-blind, placebo-controlled intervention clinical trial with three parallel arms was designed. A total of 84 patients (53 female, 31 male; age range 20-70 years) with IBS and diarrhea according to Rome-III criteria were randomly allocated to receive one capsule a day for 6 wk containing: (1) I.31 high dose (n = 28); (2) I.31 low dose (n = 27); and (3) placebo (n = 29). At baseline, and 3 and 6 wk of treatment, patients filled the IBSQoL, Visceral Sensitivity Index (VSI), and global symptom relief questionnaires.

RESULTS

During treatment, IBS-QoL increased in all groups, but this increment was significantly larger in patients treated with I.31 than in those receiving placebo (P = 0.008). After 6 wk of treatment, IBS-QoL increased by 18 ± 3 and 22 ± 4 points in the high and the low dose groups, respectively (P = 0.041 and P = 0.023 vs placebo), but only 9 ± 3 in the placebo group. Gut-specific anxiety, as measured with VSI, also showed a significantly greater improvement after 6 wk of treatment in patients treated with probiotics (by 10 ± 2 and 14 ± 2 points, high and low dose respectively, P < 0.05 for both vs 7 ± 1 score increment in placebo). Symptom relief showed no significant changes between groups. No adverse drug reactions were reported following the consumption of probiotic or placebo capsules.

CONCLUSION

A new combination of three different probiotic bacteria was superior to placebo in improving IBS-related quality of life in patients with IBS and diarrhea.

Authors+Show Affiliations

Vicente Lorenzo-Zúñiga, Jordi Serra, Gastroenterology, Motility and Functional Gut Disorders Unit, Hospital Universitari Germans Trias i Pujol/CIBERehd, 08916 Badalona, Spain.Vicente Lorenzo-Zúñiga, Jordi Serra, Gastroenterology, Motility and Functional Gut Disorders Unit, Hospital Universitari Germans Trias i Pujol/CIBERehd, 08916 Badalona, Spain.Vicente Lorenzo-Zúñiga, Jordi Serra, Gastroenterology, Motility and Functional Gut Disorders Unit, Hospital Universitari Germans Trias i Pujol/CIBERehd, 08916 Badalona, Spain.Vicente Lorenzo-Zúñiga, Jordi Serra, Gastroenterology, Motility and Functional Gut Disorders Unit, Hospital Universitari Germans Trias i Pujol/CIBERehd, 08916 Badalona, Spain.Vicente Lorenzo-Zúñiga, Jordi Serra, Gastroenterology, Motility and Functional Gut Disorders Unit, Hospital Universitari Germans Trias i Pujol/CIBERehd, 08916 Badalona, Spain.Vicente Lorenzo-Zúñiga, Jordi Serra, Gastroenterology, Motility and Functional Gut Disorders Unit, Hospital Universitari Germans Trias i Pujol/CIBERehd, 08916 Badalona, Spain.Vicente Lorenzo-Zúñiga, Jordi Serra, Gastroenterology, Motility and Functional Gut Disorders Unit, Hospital Universitari Germans Trias i Pujol/CIBERehd, 08916 Badalona, Spain.

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25024629

Citation

Lorenzo-Zúñiga, Vicente, et al. "I.31, a New Combination of Probiotics, Improves Irritable Bowel Syndrome-related Quality of Life." World Journal of Gastroenterology, vol. 20, no. 26, 2014, pp. 8709-16.
Lorenzo-Zúñiga V, Llop E, Suárez C, et al. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol. 2014;20(26):8709-16.
Lorenzo-Zúñiga, V., Llop, E., Suárez, C., Alvarez, B., Abreu, L., Espadaler, J., & Serra, J. (2014). I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World Journal of Gastroenterology, 20(26), pp. 8709-16. doi:10.3748/wjg.v20.i26.8709.
Lorenzo-Zúñiga V, et al. I.31, a New Combination of Probiotics, Improves Irritable Bowel Syndrome-related Quality of Life. World J Gastroenterol. 2014 Jul 14;20(26):8709-16. PubMed PMID: 25024629.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. AU - Lorenzo-Zúñiga,Vicente, AU - Llop,Elba, AU - Suárez,Cristina, AU - Alvarez,Beatriz, AU - Abreu,Luis, AU - Espadaler,Jordi, AU - Serra,Jordi, PY - 2013/11/06/received PY - 2014/02/05/revised PY - 2014/03/19/accepted PY - 2014/7/16/entrez PY - 2014/7/16/pubmed PY - 2015/4/14/medline KW - Irritable bowel syndrome KW - Probiotic combination KW - Quality-of-life SP - 8709 EP - 16 JF - World journal of gastroenterology JO - World J. Gastroenterol. VL - 20 IS - 26 N2 - AIM: To determine the dose-related effects of a novel probiotic combination, I.31, on irritable bowel syndrome (IBS)-related quality of life (IBS-QoL). METHODS: A multicenter, randomized, double-blind, placebo-controlled intervention clinical trial with three parallel arms was designed. A total of 84 patients (53 female, 31 male; age range 20-70 years) with IBS and diarrhea according to Rome-III criteria were randomly allocated to receive one capsule a day for 6 wk containing: (1) I.31 high dose (n = 28); (2) I.31 low dose (n = 27); and (3) placebo (n = 29). At baseline, and 3 and 6 wk of treatment, patients filled the IBSQoL, Visceral Sensitivity Index (VSI), and global symptom relief questionnaires. RESULTS: During treatment, IBS-QoL increased in all groups, but this increment was significantly larger in patients treated with I.31 than in those receiving placebo (P = 0.008). After 6 wk of treatment, IBS-QoL increased by 18 ± 3 and 22 ± 4 points in the high and the low dose groups, respectively (P = 0.041 and P = 0.023 vs placebo), but only 9 ± 3 in the placebo group. Gut-specific anxiety, as measured with VSI, also showed a significantly greater improvement after 6 wk of treatment in patients treated with probiotics (by 10 ± 2 and 14 ± 2 points, high and low dose respectively, P < 0.05 for both vs 7 ± 1 score increment in placebo). Symptom relief showed no significant changes between groups. No adverse drug reactions were reported following the consumption of probiotic or placebo capsules. CONCLUSION: A new combination of three different probiotic bacteria was superior to placebo in improving IBS-related quality of life in patients with IBS and diarrhea. SN - 2219-2840 UR - https://www.unboundmedicine.com/medline/citation/25024629/I_31_a_new_combination_of_probiotics_improves_irritable_bowel_syndrome_related_quality_of_life_ L2 - http://www.wjgnet.com/1007-9327/full/v20/i26/8709.htm DB - PRIME DP - Unbound Medicine ER -